Grail wins FDA panel backing for cancer blood test despite efficacy concerns

Traders Union
All News
Financial News
Grail cancer test FDA panel

Highlights

Grail's cancer-screening blood test receives FDA advisory panel backing for safety but faces concerns about insufficient clinical benefit for approval.
Shares of Grail surge more than 30% ahead of Wednesday's meeting, with trading halted, reflecting heightened investor anticipation around FDA review.
Results from Grail's UK NHS trial involving over 142,000 participants fail to show reduced late-stage cancer diagnoses, causing a near 50% share drop in February.

FDA panel vote and approval path

As reported by Financial Times, advisers to the Food and Drug Administration vote in favor of Grail's cancer-screening blood test at a meeting on Wednesday, while unanimously finding the product safe. The backing is nonbinding, and several doctors on the panel say they remain uneasy about whether the test delivers enough clinical benefit to justify approval.

Jason Dominitz, a gastroenterologist at the University of Washington and one of the 10 experts voting on the test, says he struggles with the decision and still has serious concerns about approving it. Grail's test is designed to detect DNA fragments in blood that may signal multiple cancers, including breast and bowel cancer, before symptoms appear.

Grail says in a statement after the meeting that it expects the FDA to make a decision in the coming months. Chief executive Josh Ofman says the panel's recommendations reaffirm the high evidence bar the company has set for a multi-cancer early detection test.

Market reaction and trial overhang

Investors are closely watching the FDA process because Grail's prospects rest heavily on the commercial potential of the test after years of corporate upheaval. Ahead of the meeting on Monday, the California biotech's shares surge more than 30%, and trading in the stock is halted on Wednesday.

Wednesday's vote comes after a turbulent period for Grail and former parent Illumina. Illumina sought to reacquire Grail in 2021 after spinning it off in 2016, and although regulators in the U.S. and EU block the deal initially, Illumina proceeds anyway, helping trigger a boardroom fight with activist investor Carl Icahn in 2023.

A major overhang remains the outcome of Grail's UK National Health Service trial involving more than 142,000 people. The study does not show a significant difference between screened participants and a control group in reducing late-stage cancer diagnoses, sending Grail shares down nearly 50% in February, though the stock later recovers and is up 27% since the start of 2026.

Our earlier report on Enveda’s $311 million Series E round highlighted that funding is still flowing to biotech firms using AI to push drug candidates from research into human trials. We noted that while no AI-discovered drug has yet won FDA approval, investor interest is rising as companies like Enveda advance multiple programs and try to prove real-world clinical and commercial potential.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.